Postoperative adjuvant chemotherapy of gastric cancer is efficient in clinic, but it is accompanied by some problems. The main problem is associated complications caused by chemotherapy, such as different degree adverse reactions of the digestive system, blood system, nervous system, chemotherapeutic drugs cause the complications occurrence of the hemocytopenia, haemoglobin reduction and thrombocytopenia resulted by myelosuppression, nausea and vomiting, diarrhea, hand foot syndrome and so on (9,10). The adverse reaction of chemotherapy was significantly reduced after the application of hyperbaric oxygen, for instance, myelosuppression, gastrointestinal reaction and hair loss in hyperbaric oxygen group improved markedly. The treatment of hyperbaric oxygen combined with chemotherapy has improved the efficacy of chemotherapy while reducing the adverse reaction of chemotherapy, which has been proved in experiments (11,12). However, the clinical application in postoperative gastric cancer has not been reported. There was a statistical difference between the experimental group and the control group in the hemocytopenia thrombocytopenia, nausea and vomiting, and peripheral nervous reaction (P<0.05), but there was no significant difference in hemoglobin reduction and diarrhea (P>0.05). Meanwhile, QLQ-C30 was performed to compare the life quality score in two groups. EORTCQLQ-C30 scale is used widely in the world, which can reflect the multidimensional structure of the life quality, it is applicable to determine the life quality of cancer patients in China (13). The results showed that the QLQ-C30 score of the experimental group was 42.32±16.20, the control group was 79.53±18.54, and the score of life quality in the experimental group was significantly lower than that in the control group, the QOL in the experimental group was significantly improved.
In this study, the application of hyperbaric oxygen combined with chemotherapy in the treatment of postoperative gastric cancer reduced the recent local recurrence rate and the side reaction, the safety, tolerance of chemotherapy and postoperative survival time of patients were markedly improved. The small sample is the main deficiency in the study, so it is not sufficient to evaluate the effect factors of postoperative adjuvant chemotherapy. Long-term survival was not assessed the follow-up time was not long enough. The long-term survival rate was not assessed as the follow-up time was not long enough. Further information was needed to improve the analysis of clinical efficacy and tolerance in postoperative chemotherapy patients and the specific mechanism in clinical application still needs to be further investigated.
Funding: This study was supported by grants from the Shanghai Municipal Commission of Health and Family Planning (grant number: 201440523).
Conflicts of Interest: The authors have no conflicts of interest to declare.
Ethical Statement: The study was approved by the Ethics Committee of Renji Hospital [(2014) 120K] and written informed consent was obtained from all patients.
Changlin Qian1, Hua Liu1, Jie Zhang, Zhiyong Shen
Department of General Surgery, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201112, China
Contributions: (I) Conception and design: Z Shen; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: J Zhang; (V) Data analysis and interpretation: C Qian, H Liu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
1These authors contributed equally to this work.
Correspondence to: Zhiyong Shen, MD. Department of General Surgery, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No. 2000 Jiangyue Road, Shanghai 201112, China. Email: [email protected].
Zou WB, Yang F, Li ZS. How to improve the diagnosis rate of early gastric cancer in China. Zhejiang Da Xue Xue Bao Yi Xue Ban 2015;44:9-14. [PubMed]
Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006;107:221-31. [Crossref] [PubMed]
Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96. [Crossref] [PubMed]
Shang Y, Feng B, Zhou L, et al. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget 2016;7:538-49. [Crossref] [PubMed]
Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers 2007;23:419-31. [Crossref] [PubMed]
Menrad H, Werno C, Schmid T, et al. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology 2010;51:2183-92. [Crossref] [PubMed]
Huang C, Sun Z, Sun Y, et al. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma. Histopathology 2012;60:793-803. [Crossref] [PubMed]
Nakamura J, Kitajima Y, Kai K, et al. HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. Int J Cancer 2010;127:1158-71. [Crossref] [PubMed]
Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25. [Crossref] [PubMed]
Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011;14:50-5. [Crossref] [PubMed]
Takiguchi N, Saito N, Nunomura M, et al. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. Cancer Chemother Pharmacol 2001;47:11-4. [Crossref] [PubMed]
Moen I, Tronstad KJ, Kolmannskog O, et al. Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. BMC Cancer 2009;9:446. [Crossref] [PubMed]
Scott NW, Fayers PM, Bottomley A, et al. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. Qual Life Res 2006;15:1103-15; discussion 1117-20. [Crossref] [PubMed]
Source: Translational Cancer Research.
Originally published June 2018.